AR and nonpapillary renal cell carcinoma: Importantly, the present study shows that patients affected by tumors with increased AR expression have a favorable clinical course with a 5-year cancer-specific survival rate of 80% in ccRCC patients (90% papRCC) compared to 67% affected by ccRCCs with low AR expression (69% papRCC).